DAX25.406 ±0,0%Est506.025 +0,1%MSCI World4.343 -0,1%Top 10 Crypto12,54 +3,6%Nas23.747 +0,1%Bitcoin80.315 +2,8%Euro1,1643 -0,2%Öl65,77 +2,3%Gold4.608 +0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 TKMS thyssenkrupp Marine Systems TKMS00 NVIDIA 918422 Novo Nordisk A3EU6F Bayer BAY001 DroneShield A2DMAA RENK RENK73 Deutsche Telekom 555750 Siemens Energy ENER6Y Infineon 623100 Lufthansa 823212 BioNTech (ADRs) A2PSR2 Allianz 840400 Amazon 906866 SAP 716460
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX nach US-Inflationsdaten stabil -- Wall Street uneins -- EZB-Ausblick: Zinserhöhung unwahrscheinlich -- AMD, Intel, Google, JPMorgan, Siemens Energy, BioNTech, Rüstungsaktien, DEUTZ, im Fokus
Top News
Bitcoin, Dogecoin, Ethereum & Co. am Nachmittag Bitcoin, Dogecoin, Ethereum & Co. am Nachmittag
US-Berichtssaison startet: DAX stabil - neues Allzeithoch über 25.500er-Marke US-Berichtssaison startet: DAX stabil - neues Allzeithoch über 25.500er-Marke
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Charles River Laboratories International Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
191,90 EUR +4,45 EUR +2,37 %
STU
223,43 USD +4,67 USD +2,13 %
BTT
Charles River Laboratories International jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.9,32 Mrd. EUR

KGV919,86Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN939391

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS1598641074

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCRL

Charles River Laboratories International Aktien News

DatumMeistgelesen
BusinesswireCharles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
BusinesswireCharles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
BusinesswireCharles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
BusinesswireCharles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
BusinesswireCharles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing
BusinesswireCharles River Laboratories to Present at J.P. Morgan Healthcare Conference
BusinesswireCharles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
BusinesswireCharles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening
BusinesswireCharles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
BusinesswireCharles River Laboratories to Present at Evercore ISI Investor Conference
BusinesswireCharles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products
PR NewswireCharles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
BusinesswireCharles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
BusinesswireCharles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023
BusinesswireCharles River Launches Real-Time Research Model Ordering, Introducing an Important Digital Innovation to Research Models & Services Business
BusinesswireCharles River Laboratories Schedules Third-Quarter 2023 Earnings Release and Conference Call
BusinesswireCharles River Laboratories Provides Access to Relevant, Well-Characterized Pediatric PDX Collection for Oncology Research
BusinesswireCharles River Laboratories Achieves 90% Renewable Electricity Globally, Announces Progress on Environmental Goals
BusinesswireCharles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
BusinesswireCharles River Announces Opening of RightSourceSM Laboratory, Supporting Stevenage Biocluster
BusinesswireCharles River Laboratories to Host Virtual Investor Day
BusinesswireCharles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica
BusinesswireCharles River Laboratories to Present at Baird and Morgan Stanley Conferences
BusinesswireCharles River Laboratories Announces Plasmid Manufacturing Collaboration with Fondazione Telethon
BusinesswireCharles River Laboratories Expands Access to AAALAC-Accredited, Turnkey Research Space in Key Markets
BusinesswireCharles River Laboratories Schedules Second-Quarter 2023 Earnings Release and Conference Call
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Charles River Laboratories International, Inc. - CRL
PR NewswireSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Charles River Laboratories International, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 18, 2023 - (NYSE: CRL)
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Charles River Laboratories International, Inc. - CRL
PR NewswireROSEN, A TOP RANKED LAW FIRM, Encourages Charles River Laboratories International, Inc. Investors to Secure Counsel Before Important July 18 Deadline in Securities Class Action - CRL
PR NewswireSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Charles River Laboratories International, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 18, 2023 - (NYSE: CRL)
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Charles River Laboratories International, Inc. - CRL
PR NewswireROSEN, LEADING INVESTOR COUNSEL, Encourages Charles River Laboratories International, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - CRL
PR NewswireCRL Investors Have Opportunity to Lead Charles River Laboratories International, Inc. Securities Fraud Lawsuit
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Charles River Laboratories International, Inc. - CRL
PR NewswireCLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Charles River Investors of a Lead Plaintiff Deadline of July 18, 2023
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Charles River Laboratories International, Inc. - CRL
BusinesswireCharles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids
BusinesswireCharles River and Curigin Collaborate to Produce Oncolytic RNAi Gene Therapy
PR NewswireCHARLES RIVER LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Ac...

Charles River Laboratories International News

Charles River Laboratories International News: auf dieser Seite finden Sie alle Charles River Laboratories International News und Nachrichten zur Charles River Laboratories International Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Charles River Laboratories International News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Charles River Laboratories International News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.